2. E. Brown-Myrie, Pharm. D. Introduction Definition An elevation of either the systolic blood pressure, the diastolic blood pressure or both. BP = CO x PVR Hypertension is a sign of many underlying disease processes, the majority of which cause no symptoms. It is a major risk factor for the development of stroke, renal failure, myocardial infarction and coronary artery disease. It affects 10 – 15% of the world’s population and often coexists with other disease conditions, diabetes being the most prevalent.
3. E. Brown-Myrie, Pharm. D. Blood Pressure Measurement and Clinical Evaluation (JNC VII) Classification and Management of Blood Pressure for Adults BP Classification Systolic (mm Hg) Diastolic (mm Hg) Normal <120 and <80 Prehypertension 120-139 or 80-89 Hypertension ‡ Stage 1 140-159 or 90-99 Stage 2 > 160 or > 100 JNC7 = Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 2003;42:1206–1252
4.
5.
6. E. Brown-Myrie, Pharm. D. Risk Stratification and Treatment Blood Pressure Lifestyle Modification Drug therapy Normal (<120/80) Encourage Without With compelling Compelling Indications Indications Pre-hypertension Yes No drug therapy Drugs to treat com- 120-139/80-89) pelling indications Stage 1 Yes Thiazide-type Drugs for the com- (140-159/90-99) diuretics for most. pelling indications ‡ May use ACEI, Other agents (diuretics. ARB, BB, CCB ACE, ARB, BB, CCB or combination as needed Stage 2 Yes Two drug As Above ( > 160/ > 100) combination for most † † Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension. ‡ Treat patients with chronic renal disease or diabetes to BP goal of <130/80. Hypertension 2003;42:1206–1252
7.
8.
9.
10. E. Brown-Myrie, Pharm. D. PHYSICAL EXAMINATION Fundoscopic examination (arteriolar narrowing, focal arteriolar constrictions, AV nicking, hemorrhages, exudates and disc edema) Neck examination (carotid bruits, distended veins, enlarged thyroid) Heart (abnormal rates & rhythms, increased size, murmurs, third and fourth sounds) Lung (rales, evidence of bronchospasm) Abdomen (bruits, enlarged kidneys, masses, abnormal aortic pulses) Extremities (diminished or absent peripheral pulses,bruits and edema)
11.
12.
13.
14. 2007 – AHA Scientific Statement E. Brown-Myrie, Pharm. D. AREA BP Target (mm Hg) General CAD Prevention <140/90 High CAD risk <130/80 CAD LVD <130/80 <120/80 Circulation. 2007;115:2761-2788
15. 2007 – AHA Scientific Statement AREA BP Target (mm Hg) Specific Drug Indications General CAD Prevention <140/90 Monotherapy or combination therapy: • ACEI (or ARB), CCB, or thiazide diuretic first-line High CAD risk <130/80 Monotherapy or combination therapy: • ACEI (or ARB), CCB, or thiazide diuretic first-line CAD LVD <130/80 <120/80 β-blocker and ACEI or ARB ACEI or ARB and β-blocker and aldosterone antagonist and diuretic Circulation. 2007;115:2761-2788